Mundipharma Ophthalmology Products Limited announced an agreement with Merck to acquire their ophthalmology portfolio for the treatment of increased ocular pressure caused by open angle glaucoma or ocular hypertension, in Australia, Canada, Latin America, Middle East, Africa and New Zealand.
The acquired portfolio consists of COSOPT®, COSOPT® Preservative ‐ Free, SAFLUTAN®, TIMOPTIC®, TIMOPTIC XE®, TIMOPTIC® Preservative ‐ Free, TRUSOPT® and TRUSOPT® Preservative ‐ Free, which cover the primary treatment methods of open-angle glaucoma. TIMOPTIC® is on the World Health Organisation’s list of essential medicines, and an important first line therapy. SAFLUTAN® is a prostaglandin analogue, the most common and effective category of drugs prescribed for glaucoma; while COSOPT®, SAFLUTAN® and TRUSOPT® all provide important therapies for patients requiring subsequent treatment.
“For Mundipharma, this acquisition is a strategic entry to the global ophthalmology sector with a strong base of proven and trusted products,” said Raman Singh, President of Mundipharma Asia Pacific, Latin America, Middle East and Africa. “Mundipharma will invest our capabilities, leverage Merck’s successful clinical history and continue the legacy of trust by providing high quality solutions that address critical patient needs and expand access to these important medications in the regions which Mundipharma covers.”
